All In MedTech

FDA Clearance Tracker · P160048

EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jun 21, 2018 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Jun 21, 2018

Approved

Time to decision

603 days

Received Oct 26, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P160048
Device name
EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM
Applicant location
Germantown, MD
Received
Oct 26, 2016
Decided
Jun 21, 2018
Decision
Approved
Supplements
28 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QCD

FDA's approval statement

As written in FDA's record.

Approval for The Eversense CGM System. The device is indicated for continually measuring glucose levels in adults (18 years and older) with diabetes for up to 90 days.The system is intended to:1) Provide real-time glucose readings;2) Provide glucose trend information; and3) Provide alerts for the detection and prediction of episodes of low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia).The system is a prescription device. Historical data from the system can be interpreted to aid in providing therapy adjustments. These adjustments should be based on patterns seen over time.The system is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code QCD (Continuous glucose monitor, implanted, adjunctive use).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Senseonics, Incorporated

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.